MCCM - Oncology Drug Development in Practice

Training Course “Oncology Drug Development in Practice”
November 22-25, 2011, Amsterdam, The Netherlands

The development of new drugs for the treatment of cancer is an important objective of many companies and academic research institutes. MCCM Meeting Management and INC Research, Inc. offer a 4-day educational activity aimed at professionals in oncology drug development. This is the continuation of the highly successful program offered annually since 2004.

Online application is still open. 90% of available places already booked. So, hurry if you don't want to miss this year's course.

Click here to view the latest version of the educational schedule and confirmed faculty.

Education offered
Developing new anticancer agents is distinctly different from drug development in most other therapeutic areas. This intensive training course provides specific knowledge on the preclinical and clinical development of new anticancer agents, in particular in Europe. The course will also address relevant strategic, regulatory and scientific issues in drug development. Since successful anticancer drug development requires a basic understanding of tumor biology, cancer diagnosis, and routine patient management, an important part of the course will be devoted to tumor biology, pathology and clinical management of patients with cancer. Click here for more...

Course format and schedule
The course is organized in topic-oriented sessions, presented by expert faculty from academia and industry. There will be ample opportunity for interaction with the faculty during the course. A maximum of 30 participants will be accepted to secure the optimal educational setting. Click here for more...

Faculty
Experts in the relevant disciplines of oncology and anticancer drug development will present the various topics. Faculty members are renowned experts from leading academic research institutes and oncology-orientated drug companies, ensuring highly up-to-date education based upon hands-on experience in drug development practice. Click here for more...

Who should participate?
The course is intended for everyone who wishes to acquire (or improve) knowledge of the development of new anticancer agents, primarily professionals in industry and the CRO environment. An understanding of the basic principles of biology and medicine at graduate level is required for successful participation in the course.

Part A of the course will serve as an introduction to general and medical oncology and may be booked separately. This part is of interest to new business development, marketing, medical and regulatory department employees, and other functions.

Venue
Dorint Hotel Amsterdam Airport **** on the outskirts of Amsterdam, in the immediate vicinity of Amsterdam Schiphol Airport (transfer time approx. 10 minutes; complimentary shuttle bus available).

Fees
Full participant (part A and B): EUR 3,350
Part A only: EUR 1,950
Part B only: EUR 2,150

Fees include coffee/tea/refreshments and lunch on all course days, dinner on November 22 and 24, and unlimited wireless internet access. Not included in the fees above are: VAT, hotel accommodation, parking costs, and dinner on November 23.

Applying for the course
Click here to access online registration and hotel reservation. For group registrations (max. 5 per company) please contact us at This e-mail address is being protected from spam bots, you need JavaScript enabled to view it .

Hotel accommodation
Hotel accommodation at the course venue may be booked during online registration for the course. The recuced rate for course participants is EUR 170 per night, including breakfast, city tax and wireless internet.

Course management and information
MCCM Meeting Management BV
P.O. Box 77
3480 DB Harmelen
The Netherlands
Tel: +31 (0)88-089 8100
Fax: +31 (0)88-089 8109
Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it